The PARAGON-HF (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction) trial evaluated the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan against valsartan alone in patients with HFpEF. The gene discussed is MME; the disease is heart failure.